A Phase 3 Study of Epcoritamab Plus Standard Treatment Compared to Standard Treatment Alone in People With Follicular Lymphoma


Full Title

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)


Researchers in this study are comparing standard follicular lymphoma treatment to standard treatment plus epcoritamab. The standard treatment for follicular lymphoma is rituximab and lenalidomide. The people in this study have follicular lymphoma that keeps growing or came back even after treatment.

Epcoritamab may help your immune system better attack cancer cells. It is a type of drug called a bispecific antibody. It is designed to bind to two different proteins at one time. One protein is on the surface of cancer cells and the other protein is on immune cells called T cells. 

Epcoritamab is given as an injection under the skin. Rituximab is given as an intravenous injection, and lenalidomide is taken orally (by mouth). If you join this study, you will be randomly assigned to receive one of these treatments:

  • Epcoritamab, rituximab, and lenalidomide
  • Rituximab and lenalidomide alone

Who Can Join

To join this study, there are a few conditions. You must:

  • Have follicular lymphoma that came back or keeps growing after treatment.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Lorenzo Falchi’s office at 646-608-3705.




Phase III (phase 3)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID